Effect of ketamine infusion in treatment resistant depression and in depressive patients with active suicidal ideations: a study from North India

作者
Ubaid Rasool,Neelofer Jan,Marya Zahoor,Fazle Roub,Yasir Hassan Rather,Arshad Hussain,Rukhsana Najeeb
出处
期刊:International Journal of Research in Medical Sciences [Medip Academy]
卷期号:11 (2): 535-543 被引量:3
标识
DOI:10.18203/2320-6012.ijrms20230029
摘要

Background: Treatment resistant depression can be a life-threatening condition as it leads to an increase of suicide attempts by two to three folds. It has been estimated that nearly 1 million people die due to suicide every year, and more than two-third of these cases occur when the person is undergoing a major depressive episode. Ketamine is an NMDA receptor antagonist, an anesthetic agent that is short acting and has recently been used as an antidepressant and anti-suicidal agent. It has been seen that a single intravenous infusion of ketamine at a lower dose. i.e., subanesthetic dose of 0.5 mg/kg over a period of 40 minutes produces antidepressant effect which lasts for about a week and various studies have proved that repeated infusions of ketamine can prolong the duration of the antidepressant response. Methods: It was an observational/descriptive study done in the ketamine clinic/ECT suite of institute of mental health and neurosciences Kashmir (an associate hospital of government medical college Srinagar) which runs once a week. In this study, patients satisfying the criteria of TRD and depressive patients with active suicidal ideations, visiting the ketamine clinic who had given a valid informed consent for ketamine infusion enrolled and observed for ketamine efficacy by using specific scales. The study done over a period of 18 months from January 2020 till July 2021. Results: The response rate of ketamine in our study for treatment resistant depression was 70.27%. The response rate of ketamine for suicidality in our study was 63.16%. Our study showed a rapid onset of action for ketamine, two hours after ketamine infusion. Conclusions: A significant fraction of patients suffering from major depressive disorder do not respond to antidepressants and have a poor psychosocial functioning and an increased risk of suicide attempts making their condition life threatening. These patients therefore require special attention to address their underlying condition as well as suicidality to improve their outcome. In this context we studied the role of intravenous ketamine infusion in these patients in improving the psychosocial outcome as well as preventing the suicidal ideation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
秋风完成签到,获得积分0
1秒前
2秒前
科研通AI6.2的应助被Jeff采纳,获得10
5秒前
7秒前
飞得更高发布了新的文献求助10
8秒前
负责以山完成签到 ,获得积分10
9秒前
贤惠的咖啡完成签到,获得积分10
11秒前
细心的代天完成签到 ,获得积分10
12秒前
酷波er的应助被Jeff采纳,获得20
16秒前
体贴凌寒完成签到 ,获得积分10
17秒前
冷冷完成签到 ,获得积分10
19秒前
李狗蛋完成签到,获得积分10
20秒前
飞得更高完成签到,获得积分10
21秒前
归海一刀完成签到 ,获得积分10
22秒前
pmsl完成签到,获得积分10
22秒前
小章鱼完成签到 ,获得积分10
22秒前
24秒前
数乱了梨花完成签到 ,获得积分0
26秒前
subbrilliance完成签到 ,获得积分10
26秒前
王旭完成签到,获得积分10
27秒前
魔幻友菱完成签到 ,获得积分10
27秒前
不羁的风完成签到,获得积分10
29秒前
梦华老师发布了新的文献求助10
29秒前
BlossomGuard完成签到,获得积分10
29秒前
道道sy完成签到,获得积分10
31秒前
成就鑫完成签到 ,获得积分10
32秒前
32秒前
33秒前
HCody完成签到 ,获得积分10
33秒前
36秒前
畅快远望完成签到 ,获得积分10
38秒前
拂晓完成签到 ,获得积分10
38秒前
kk完成签到 ,获得积分10
39秒前
40秒前
Metaverse完成签到 ,获得积分10
41秒前
42秒前
keyan完成签到,获得积分10
42秒前
Jason完成签到 ,获得积分0
42秒前
44秒前
小咸鱼完成签到 ,获得积分10
45秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Energie-Contracting 1500
Klimaschutzrecht durch den Energiesektor im Mehrebenensystem – Ein Rechtsvergleich 1000
Représentation chimique de la structure des kérogènes et des asphaltènes en fonction de leur origine et de leur degré d'évolution 800
Oncology Clinical Trials: Successful Design, Conduct, and Analysis, Second Edition 800
Stochastic Models in Operations Research,Vol. 2 600
Elektrische Feldverteilung in gasisolierten Anlagen unter Gleichspannungsbelastung 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8056941
求助须知:如何正确求助?哪些是违规求助? 9482616
关于积分的说明 21313720
捐赠科研通 7624951
什么是DOI,文献DOI怎么找? 3394767
关于科研通互助平台的介绍 2525837
邀请新用户注册赠送积分活动 2433155